Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants (ValEAR)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03107871 |
Recruitment Status :
Active, not recruiting
First Posted : April 11, 2017
Last Update Posted : February 24, 2022
|
Sponsor:
Albert Park
Collaborators:
National Institute on Deafness and Other Communication Disorders (NIDCD)
Genentech, Inc.
Information provided by (Responsible Party):
Albert Park, University of Utah
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Results Submitted - Quality Control (QC) Review Has Not Concluded
Results information for an applicable clinical trial (ACT) is posted within 30 days of
submission even if the submission has not completed the
ClinicalTrials.gov Results Quality Control (QC) review process.
Results information is submitted to ClinicalTrials.gov by the sponsor or investigator,
and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff
do not verify the scientific validity or relevance of the submitted information.
All versions of ACT results information submissions that have not completed the QC review process are posted on ClinicalTrials.gov (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | July 2022 |
Estimated Study Completion Date : | July 2024 |
Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
---|---|---|
1 |
May 20, 2023 | June 15, 2023 Submission with QC Comments |
2 |
February 22, 2024 | March 19, 2024 Submission with QC Comments |
3 |
April 2, 2024 | April 30, 2024 Submission with QC Comments |